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Abstract: The aim of this multicenter prospective study was to evaluate the incidence   
of invasive fungal infections (IFIs) in adult and pediatric patients with hematologic 
malignancies, involving nine nosocomial facilities in Southern Italy over a period of   
18 months. Furthermore, results of an environmental microbial surveillance routinely 
carried out in some of the enrolled hospitals are reported. A total of 589 onco-
hematological patients were enrolled and 27 IFIs were documented. The main infections 
were caused by yeasts, more than filamentous fungi (overall incidence of 2.7% and 1.9%, 
respectively). The yeasts were mainly represented by Candida spp. (87.5%), all isolated by 
blood cultures; C. parapsilosis was the most common species. Among mould infections, 
the most frequent site was the lung, with regard to aspergillosis (81.8%). In six of the 10 
patients with suspected aspergillosis, the diagnosis was made by the detection of 
galactomannan and (1,3)-β-D-glucan antigens. The microbiological surveillance carried out 
OPEN ACCESSInt. J. Mol. Sci. 2012, 13 775 
 
 
on 156 air, 312 water and 312 surface samples revealed low environmental contamination:  
Alternaria alternata was the only fungus isolated from two surface samples. Our data, 
especially the low occurrence of filamentous fungi, suggest a particular local epidemiology. 
Further studies are needed to confirm this microbiological trend in onco-hematological 
patients in Southern Italy, the results of which might be helpful to improve the 
management of these patients. 
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1. Introduction 
The epidemiology of invasive fungal infections (IFIs) in onco-hematological patients has changed 
substantially in recent years and its incidence varies considerably among different nations [1–3].   
A special vulnerability to these infections is introduced by risk factors related to the underlying disease 
(e.g., neutropenia especially for acute myeloid leukemia patients, steroids usage, high dose cytarabine, 
invasive medical devices) [4,5], genetic profile [6,7], pre-hospital and hospital exposure [8], age,   
and comorbidities.  
Among IFIs caused by yeasts, Candida albicans remains an important pathogen, but a rising rate of 
infections is caused by non-albicans Candida species (i.e., C. glabrata, C. guilliermondii, C. parapsilosis, 
C. tropicalis and C. krusei) [9–11].  
Over the last 20 years, an increasing number of infections caused by moulds has been reported: 
Aspergillus spp. seems to be the main fatal complication in patients with hematological malignancies, 
but other opportunistic moulds, such as Fusarium spp. and Zygomycetes, have also been described [12], 
whereas infections caused by other filamentous fungi are still rare [13,14].  
Although the actual incidence of the IFIs has increased, its real frequency is often underestimated 
because of the difficulty in diagnosis [15]. In fact, although the use of laboratory tests has expanded  
in recent years, IFIs diagnosis continue to be hampered by non-specific clinical manifestations   
and difficulties in obtaining appropriate biological samples for mycological investigations. Such 
investigations usually require invasive procedures (e.g., histological samples, bronchoalveolar lavage) 
often precluded by cytopenia or by the critical condition of these patients. Moreover, the newer 
diagnostic approaches, focusing on the detection of surrogate markers such us circulating fungal 
antigens or metabolites (e.g., galactomannan and (1,3)-β-D-glucan), need serum samples repeated over 
time because of their occasional presence in the blood [15]. 
This study is a subset of the AURORA Project, the first active surveillance program carried out in 
Apulia (Southern Italy) to assess the incidence of IFIs in patients admitted to the Intensive Care, 
Hematology and Neonatal Intensive Care Units. It was launched in February 2007 and approved by the 
Ethics Committee of the Azienda Ospedaliero-Universitaria Policlinico of Bari, Italy.  
The present study reports the incidence of IFIs in onco-hematological patients, the characteristics of 
enrolled patients, and the role of the additional biomarkers-diagnostic tests. Moreover, the results from 
an environmental surveillance carried out on water, surface and air samples are reported.  Int. J. Mol. Sci. 2012, 13 776 
 
 
2. Material and Methods 
2.1. Study Design 
Apulia is a region located in Southern Italy with about 4 million inhabitants, 38,000 births/year and 
a mean of 850,000 hospital admissions/year. All the regional hospitals admitting onco-hematological 
patients were involved in the AURORA project, for a total of nine nosocomial facilities: five admitting 
adult patients and four both adult and pediatric patients. 
To standardize the clinical recruitment and microbiological procedures, a training course was 
organized before starting the study, and a manual was distributed to all participants. 
The study was carried out over 18 months (February 2007–August 2008) on adult (aged over 16 years 
old) and pediatric (under 16 years old) patients with newly diagnosis of one of the following diseases: 
  acute myeloid (AML) or acute lymphoid leukemia (ALL); 
  chronic lymphocitic (CLL) or chronic myeloid leukemia (CML); 
  Hodgkin’s (HL) or non-Hodgkin’s lymphoma (NHL); 
  Multiple myeloma (MM)  
Moreover, patients with autologous or allogeneic hematopoietic stem cell transplantation (HSCTs) 
following one of the previously mentioned onco-hematological malignancies were enrolled.  
Patients with non-malignant hematological disorders (hemolytic anemia, thrombocytopenias, aplastic 
anemia, etc.) were excluded from the study. 
In accordance with the criteria proposed by Ascioglu [16] and taking into account the clinical   
data of enrolled patients, biological samples from potentially infected sites (e.g., blood, peritoneal and 
cerebrospinal fluid, bronchial aspirate, sputum) were sent to each hospital-associated microbiology 
laboratory for the mycological analysis, where all fungal species were eventually isolated, identified 
and stored. Moreover, the circulating antigens (1,3)-β-D-glucan (BDG) and galactomannan (GM) were 
performed only in patients with suspected moulds disease (e.g., positive culture or instrumental tests, 
persisting fever, chest pain, etc.). Serum samples were analyzed thrice weekly until discharge or death. 
For each enrolled patient, the participating centre had also to complete an electronic report form 
including information about the patient (age, sex, underlying disease), microbiological data (date of first 
culture, etiological agents, circulating antigens), histological and/or radiological evidence, therapeutic 
approach and outcome 30–60 days after enrolling.  
In order to confirm the identification of species and to analyze the data, both the isolates and the 
electronic reports were sent to the Coordinating Centre (Laboratory of Mycology, Department of 
Biomedical Sciences and Human Oncology, University of Bari “Aldo Moro”). 
As indicated in the study protocol, the pharmacological management of the onco-hematological 
adult patient was made according to ECIL 2007 [17] and IDSA 2008 [18] guidelines. In particular, 
prophylaxis was performed with Fluconazole (400 mg daily until recovery of neutrophils). In case  
of fever unresponsive to an adequate (at least 96 h) empiric broad spectrum antibiotic therapy, we 
proceeded with an empiric antifungal therapy using intravenous Caspofungin (loading dose of 70 mg, 
then 50 mg daily) or Lipid Formulation (LF) of Amphotericin B (3 mg/kg daily). Voriconazole 
(loading dose of 6 mg/kg × 2, then 3 mg/kg × 2 daily) or Caspofungin or LF Amphotericin B were also Int. J. Mol. Sci. 2012, 13 777 
 
 
used in case of microbiological evidence coming from patients undergoing close surveillance (i.e., serum 
detection of galactomannan antigen, detection of respiratory tract colonization by filamentous fungi 
and/or CT and ultrasonographic examination according to clinical features).  
In the pediatric population the use of antifungal prophylaxis (Fluconazole at 6 mg/kg daily) was 
reserved for patients with severe neutropenia (PMN < 500/mm
3), while an empiric antifungal therapy 
with Caspofungin (50 mg/m
2 daily) or LF Amphotericin B (3 mg/kg daily) was administered in case of 
fever unresponsive to an adequate antibiotic therapy.  
Furthermore, because an environmental microbial surveillance was carried out three times per year  
in the bone marrow transplant units located in 4 out of the 9 enrolled hospitals, a hypothetic association 
between the IFIs cases and the environmental fungal surveillance was evaluated. These wards are 
equipped with a laminar air-flow (LAF) system with HEPA filters. Each room has a positive airflow 
control device. 
2.2. Case Definition  
The diagnosis of invasive fungal disease was made according to the definition proposed by the 
EORTC/MSG [19]. Our analysis was restricted to infections classified as “proven” or “probable”. 
The duration of fungemia was defined as the time interval (days) between the first and last positive 
blood cultures (yielding the same pathogen). Persistent fungemia was defined as the persistence of 
positive blood cultures for >2 days, from the time of the first positive blood culture.  
2.3. Laboratory Procedures 
Each biological sample (e.g., sputum, nasal swab) was cultured on two Sabouraud chloramphenicol 
dextrose agar (SDA) plates (bioMèrieux, Marcy l’Etoile-France), incubated at 36 ± 1 °C and 28 °C 
(for yeasts and moulds isolation) and examined daily for 10 days.  
Identification of yeasts was performed with sugar assimilation profiles obtained using the ID32C 
and confirmed by VITEK-2 System (Biomérieux, Marcy l’Etoile, France).  
Filamentous fungi were identified on the basis of their macroscopic and microscopic morphological 
features, in accordance with standard methods [20]. 
The presence of the BDG antigen was measured by colorimetric assay, Fungitell (Associates of 
Cape Cod Inc., E. Falmouth, MA, USA); the GM antigen was measured using a commercial sandwich 
immunoassay (Platelia Aspergillus Ag—BioRad, Marnes La Coquette, France). All tests were performed 
according to the manufacturer’s instructions. 
2.4. Environmental Surveillance  
Overall, 156 air, 312 water and 312 surface samples provided by the four hospitals including bone 
marrow transplant units (for a total of 26 onco-hematological patient’s rooms) were examined. SDA 
plates were employed to yield fungi, incubated at 36 ± 1 °C and 28 °C (for yeasts and moulds isolation) 
and examined daily for up to 10 days.  
Air samples (180 L/min for a total suction volume of 500 L) were collected using a Surface Air 
System (SAS) sampler (Microflow Acquaria, Milan, Italy). It was placed in each monitored room about Int. J. Mol. Sci. 2012, 13 778 
 
 
1 m above the floor and 1 m from the patient’s bed. The number of colony forming units was adjusted 
using the conversion table provided by the manufacturer and was expressed in colony forming units 
per cubic meter (cfu/m
3) [21]. 
For mycological water contamination, tap and shower water samples were collected in sterile bottles 
and immediately transported to the laboratory in cool boxes, in accordance with Italian legislation [22].  
Fungal contamination of surfaces was evaluated at the patient’s bedhead and on the air aspiration 
grate, using sterile swabs [23]. The results were expressed as cfu/cm
2.  
2.5. Statistical Analysis  
Data were entered into a computer database (Microsoft Access 2003). Categorical variables were 
expressed as proportions or percentages, and numerical data were expressed as the mean ± SD and range.  
Univariate analysis was performed using the χ
2 test and Fisher’s exact test where appropriate with 
each of the following independent variables: age group (0–16, 17–40, 41–60, 61–80), sex, underlying 
hematological diseases, host factors and autologous or allogeneic hematopoietic stem cell 
transplantation (HSCTs). Variables for which data sets were incomplete were not included. Multivariate 
analysis was performed using a logistic regression model applying the stepwise selection to identify 
significant associations between host factors and risk of developing an IFI. Adjusted odds’ ratio (OR) 
and 95% confidence interval (CI) were calculated. A p < 0.05 was considered statistically significant. 
The analyses were performed using the software SAS system version 9.2. 
The overall and IFI-attributable mortality rates (AMR) were estimated. As reported by   
Pagano et al. [14], we considered the “overall mortality” as the ratio of deaths affected by IFIs to the 
total number of enrolled patients and the AMR as the ratio of deaths in patients affected by IFIs to the 
number of enrolled patients affected by IFIs. 
To evaluate the association between environmental fungal surveillance and presence/absence of 
IFIs, data regarding number of hospitals with and without a periodical environmental monitoring and 
number of hospitals with and without IFIs were entered in a contingence table. The relative risk (RR) 
and the confidence interval at 95% were calculated. The Chi-square test was applied to evaluate the 
significance of association between variables, considering significant a p-value < 0.05. 
3. Results  
During the 18-months study, 589 patients with newly diagnosed hematological malignancies were 
enrolled (475 adults and 114 pediatrics). Their underlying hematological diseases and host factors are 
shown in Table 1. 
Twenty-seven episodes of IFIs were documented: overall incidence 4.6% (5% in adults and 2.6%  
in pediatric patients). The male/female ratio was 13/11 in the adult population (mean age at   
diagnosis = 53.6 ± 16.6 years; range, 19–78) and 2/1 in the pediatric population (mean age at   
diagnosis = 6 ± 6.1 years; range, 2–13). The most common underlying disease was AML (40.7%), 
followed by NHL (18.5%), ALL (14.8%), CLL and MM (11.1%, respectively) and HD (3.7%).  Int. J. Mol. Sci. 2012, 13 779 
 
 
Table 1. Demographics and clinical characteristics of 589 enrolled patients. 
Characteristics 
All patients (n = 589) 
No. (%) 
Adults (n = 475) 
No. (%) 
Pediatric (n = 114) 
No. (%) 
Sex      
Male  383 (65)  290 (61)  93 (81.6) 
Female  206 (35)  185 (38.9)  21 (18.4) 
Age-mean ± SD (years)  47.7 ± 23.4  57.3 ± 13.7  7.4 ± 5.7 
[range]   [2–80]  [19–80]  [2–16] 
0–16  114 (19.3)   —  114 (100) 
17–40  14 (2.4)  14 (2.9)  — 
41–60  200 (33.9)  200 (42.1)  — 
61–80  261 (44.3)   261 (54.9)  — 
Underlying hematological diseases       
AML  204 (34.6)  195 (41)  9 (7.9) 
ALL  136 (23.1)  48 (10.1)  88 (77.2) 
CML  5 (0.8)  5 (1.0)  0 
CLL  10 (1.7)  10 (2.1)  0 
NHL  147 (24.9)  140 (29.7)  7 (6.1) 
HD  15 (2.5)  5 (1.0)  10 (8.8) 
MM  72 (12.2)  72 (15.1)  0 
Host factors       
Chemotherapy  580 (98.5)  466 (98.1)  114 (100) 
Central venous catheter   343 (58.2)  238 (50.1)  105 (92.1) 
Prolonged antibiotic therapy  223 (37.9)  143 (30.1)  80 (70.2) 
Neutropenia < 500 PMN/mm³  410 (69.6)  333 (70.1)  77 (67.5) 
Neutropenia: 500–1000 PMN/mm³  179 (30.4)  142 (29.9)  37 (32.4) 
Immunosuppressive therapy  138 (23.4)  24 (5.0)  114 (100) 
Corticosteroids  209 (35.5)  95 (20)  114 (100) 
Parenteral nutrition  101 (17.1)  95 (20)  6 (5.3) 
Surgery  25 (4.2)  5 (1)  20 (17.5) 
Cytomegalovirus infection  12 (2)  12 (2.5)  0 
HSCT      
Allogeneic bone marrow transplant  15 (2.5)  15 (3.1)  0 
Autologous bone marrow transplant  30 (5.1)  30 (8)  0 
AML: acute myeloid leukemia; ALL: acute lymphoid leukemia; CML: chronic myeloid leukemia; 
CLL: chronic lymphocitic leukemia; NHL: non-Hodgkin’s lymphoma; HD: Hodgkin’s disease; 
MM: multiple myeloma; HSCT: hematopoietic stem cell transplantation. 
Of the 27 documented IFIs, 16 were caused by yeasts (13 in adult patients: incidence 2.7% and 3 in 
pediatric patients: incidence 2.6%) and 11 by filamentous fungi (all in adult patients: incidence 2.3%). 
No filamentous fungi infections in pediatric patients were reported. 
Table 2 shows the IFIs incidence by yeasts and moulds distributed for different types of 
hematologic malignancies, host factors and hematopoietic stem cell transplantation (autologous and 
allogeneic bone marrow transplant). In adult patients, the incidence ranged between 1.4% among 
patients with NHL and 4.1% in those with AML for yeasts infections; between 1.4% among patients Int. J. Mol. Sci. 2012, 13 780 
 
 
with NHL and MM and 30% in those with CLL for moulds infections. Pediatric patients developed 
only yeasts infections, whose incidence was 14.3% among patients with NHL and 2.3% in those with 
ALL. Of the 27 patients, 5 underwent hematopoietic stem cell transplantation: three autologous and 
two allogeneic bone marrow transplants. The three patients with autologous bone marrow transplant  
(2 MM and 1 NHL) had only yeasts IFIs; the two patients with allogeneic bone marrow transplant 
(both AML) had one yeast and one mould IFI respectively.  
Table 2. Incidence of invasive fungal infections (IFIs) in adult and pediatric patients. 
Hematologic malignancies 
Adult patients   Pediatric patients 
Yeasts IFI 
No./Total 
(Incidence %)
Moulds IFI 
No./Total 
(Incidence %) 
Yeasts IFI 
No./Total 
(Incidence %) 
AML  8/195 (4.1)   3/195 (1.5)  0 
ALL  1/48 (2.1)  1/48 (2.1)  2/88 (2.3) 
CLL 0  3/10  (30)  - 
NHL  2/140 (1.4)  2/140 (1.4)  1/7 (14.3) 
HD 0  1/5  (20)  0 
MM  2/72 (2.8)  1/72 (1.4)  - 
Host factors      
Chemotherapy 7/466  (1.5)    5/466 (1.1)  3/114 (2.6) 
Central venous catheter   9/238 (3.8)  5/238 (2.1)  3/105 (2.8) 
Prolonged antibiotic therapy  4/143 (2.8)  2/143 (1.4)  0 
Neutropenia <500 PMN/mm³  5/333 (1.5)  9/333 (2.7)  2/77 (2.6) 
Neutropenia: 500–1000 PMN/mm³  1/142 (0.7)  1/142 (0.7)  1/37 (2.7) 
Immunosuppressive therapy  2/24 (8.3)  1/24 (4.2)  3/114 (2.6) 
Corticosteroids  0  4/95 (4.2)  3/114 (2.6) 
Parenteral nutrition  4 (4.2)  0  0 
Surgery 1  (20)  0  0 
Cytomegalovirus infection  0 2/12  (16.7)  0 
HSCT      
Allogeneic bone marrow transplant  1/15 (6.7)  1/15 (6.7)  - 
Autologous bone marrow transplant  3/30 (10)  0  - 
AML: acute myeloid leukemia; ALL: acute lymphoid leukemia; CLL: chronic lymphocitic 
leukemia; NHL: non-Hodgkin’s lymphoma; HD: Hodgkin’s disease; MM: multiple myeloma; 
HSCT: hematopoietic stem cell transplantation. 
Regarding the antifungal treatment, 67% of our patients were undergoing empiric therapy. The 
overall fungal infections mortality rate was 1% (6/589 patients) and the AMR was 22.2% (6/27 cases). 
Fisher’s exact test showed a significant difference between AMR for mould vs. yeast infections 
(45.4% vs. 6.25%; p = 0.026); it must be considered that no pediatric patient died. 
3.1. Yeast Infections 
Of the 27 diagnosed cases, 16 (59.2%) were caused by yeasts, all based on blood cultures: 13 were 
adult (male/female ratio was 8/5) and 3 pediatric patients (male/female ratio was 2/1). The majority of Int. J. Mol. Sci. 2012, 13 781 
 
 
yeasts isolates were Candida spp. (87.5%); C. parapsilosis was the most frequently isolated species in 
adult (36.4%), followed by C. tropicalis, C. krusei,  C. glabrata (18.2% respectively) and   
C. guilliermondii (9%). Cryptococcus neoformans and  Geotrichum capitatum (both 6.2%) were   
also isolated.  
With regard to adult patients, the underlying diseases were AML (61.5%), NHL (15.4%),   
MM (15.4%) and ALL (7.7%). Among the host factors, the presence of a central venous catheter (CVC) 
resulted the most frequent (69.2%), followed by chemotherapy (cytarabine in all cases) (53.8%), 
severe neutropenia (38.5%, with a mean duration of 7 ± 1.6 days; range 6–11), prolonged antibiotic 
therapy (30.8%), and immunosuppressive therapy (15.4%) with cyclosporine. Moreover, four were 
bone marrow transplant patients: autologous transplants (23.1%) were more frequent than allogeneic 
ones (7.7%). The mean age of adult patients at diagnosis was 55.1 ± 14.6 years (range 19–77). The 
time of infection onset was 15 ± 16.1 days (range 0–55) from the first day of recovery; the mean 
duration of fungemia was 3.8 ± 6.3 days (range 1–24); persistent fungemia was found in four patients 
(30.8%—range, 4–24 days). Just one adult patient with yeast infection and MM who underwent 
autologous bone marrow transplant died. In five adults, at the moment of the IFI suspect and after the 
blood sampling, the CVC was removed and underwent catheter tip cultures. In all cases, the blood 
culture tested positive for Candida parapsilosis; moreover, three CVC resulted positive for the same 
fungal species (C. parapsilosis) and two were negative. 
With regard to pediatric patients with yeasts IFI, the underlying diseases were ALL (2/3: 66.6%) 
and NHL (1/3: 33.3%). They had a central venous catheter and were under chemotherapy, 
immunosuppressive therapy, and use of corticosteroids; moreover, 66.6% of them showed severe 
neutropenia. The mean age of pediatric patients at diagnosis was 6 ± 6.1 years (range 2–13), the mean 
duration of fungemia was 4 ± 3 days (range 1–7); persistent fungemia was found in two patients (4 and  
7 days, respectively). The time of onset of infection from the first day of recovery was 19.3 ± 19.6 days 
(range 1–40), caused by C. albicans, C. lusitaniae and C. parapsilosis (33.3% respectively). The three 
children with IFI did not have the CVC removed. 
Univariate analysis showed that—in adult patients—chemotherapy (p < 0.0001), autologous bone 
marrow transplant (p < 0.05) and severe neutropenia (p < 0.05) were significantly associated with 
yeasts IFIs. Moreover, the stepwise regression analysis did not show any significant risk factor for 
developing yeasts IFIs. With regard to yeasts infections in children, univariate and multivariate 
analysis did not show any risk factors for developing IFI.  
3.2. Mould Infections 
A total of eleven mould infections (40.7%, 10 aspergillosis and 1 zygomycoses) were reported only 
in adult patients (incidence 2.3%). The overall male/female ratio was 5/6. The mean age at diagnosis 
was 51.8 ± 19.2 years (range 21–78).  
Underlying diseases were AML and CLL (27.3%, respectively), NHL (18.2%), HD, ALL and MM 
(9.1%, respectively). 
Severe neutropenia (<500 PMN/mm
3) resulted the most frequent host factor (81.8%), followed by 
central venous catheter (45.5%), corticosteroids therapy and chemotherapy (36.4%, respectively), 
prolonged antibiotic therapy and Cytomegalovirus infection (18.2%, respectively). Int. J. Mol. Sci. 2012, 13 782 
 
 
The most common site of infection was the lung, with regard to aspergillosis (81.8%). These 
patients presented a CT scan suggestive of moulds infection, but only in three cases the etiological 
agents were isolated from respiratory secretions and identified at the species level (A. fumigatus). The 
remaining two patients were positive in different sites, one for Aspergillus fumigatus recovered by two 
blood cultures and one for Rhizomucor pusillus by a retrosternal lesion.  
BDG, GM antigens detection was performed in all eleven patients, for a total of 39 sera. BDG 
tested positive (>80 pg/mL) in all the 38 sera samples from patients with aspergillosis (10/11), while 
GM antigen tested positive (Index cut-off > 0.5) in 36 of the same 38 sera samples. Using BDG and 
GM assays, an aspergillosis diagnosis was possible in 6 of the 10 patients with suspected aspergillosis, 
in which the culture survey was negative.  
The AMR in adult patients was estimated at 45.4% (5/11 cases): one AML patient had undergone 
an allogeneic bone marrow transplant (9.1%), two patients were affected by NHL (18.2%) and two by 
CLL (18.2%). 
Univariate analysis showed that chemotherapy (p < 0.0001) and Cytomegalovirus  infections  
(p < 0.01), were significantly associated with mould IFIs in adult patients. Moreover, the stepwise 
regression analysis confirmed only Cytomegalovirus  infection (p = 0.0012; OR 15.419; CI 95%   
1.814–131.103) to be a risk factor for developing mould IFIs.  
With regard to the pediatric patients, no mould IFIs were detected. 
3.3. Environmental Surveillance  
In four Hematology units, including bone marrow transplant wards, equipped with HEPA filters 
and undergoing environmental monitoring, fungi were never isolated from air/water samples collected 
from patients’ rooms; only Alternaria alternata was isolated from two surface samples collected at the 
same time from a room. In these hospitals a single case of mould IFI was diagnosed.  
In the remaining five hospitals without HEPA filters and not undergoing environmental monitoring, 
10 mould IFIs were detected. 
Since this surveillance yielded a small number of IFIs, an association between the results of 
environmental surveillance and frequency of IFIs was not possible. 
4. Discussion  
In Apulia region the IFIs affecting onco-hematological patients appear to be caused more commonly 
by yeasts than by filamentous fungi (59.2% vs. 40.7%), with an overall incidence of 2.7% and   
1.9% respectively.  
Among yeasts, Candida non albicans (CnA) species were the most frequently isolated, according  
to a retrospective study carried out during 1998–2004 in one of the hospitals enrolled in the present 
survey [24]. These data revealed an evident increase of CnA candidemia, particularly C. parapsilosis in 
Hematology and Pediatric Oncology Units. By contrast, C. albicans was the major cause of candidemia 
in the other wards. Also in our study C. parapsilosis resulted in the most frequent CnA species (38.5%). 
Although this yeast is one of the less virulent species of Candida, its role in epidemiology of blood 
stream infections is very important because it is often responsible for healthcare-associated infections 
(e.g., intravascular catheters and parenteral nutrition) [25].  Int. J. Mol. Sci. 2012, 13 783 
 
 
Other yeasts isolated from blood were Cryptococcus neoformans and Geotrichum capitatum  
(6.2% both) in two different AML patients. These data are in accordance with other reports that show  
a lower incidence of blood stream infections caused by these yeasts in patients with hematologic 
malignancy [13,14].  
Regarding mould infections, we found a low incidence in adult patients (11/475; 2.3%) and no case 
in the 114 pediatric patients. We realize that these data are not according to those reported by other 
authors. In fact, recent studies indicate that: 
  AML patients are at highest risk of developing an IFI [14,26]. Our data confirm these findings 
only with regard to yeast infections. Paradoxically, the incidence of mould infections was higher in 
patients with CLL (30%) than in those with AML (1.5%, one proven zygomycosis and two 
probable aspergillosis), probably because of the wide use of monoclonal antibodies therapy 
(Alemtuzumab), that the CLL patients receive for 18 weeks. In fact, in a recent study   
some authors [27] state that the incidence of moulds IFIs increases after this kind of 
immunosuppressive therapy. 
  Besides  Aspergillus spp., other moulds (i.e.,  Zygomycetes,  Fusarium,  Scedosporium) are 
emerging, probably related to the use of more aggressive chemotherapy [14]. In our survey, only 
one out of 11 mould infections was caused by Zygomycetes, in a patient undergoing more than 
three lines of chemotherapy. 
  Pagano et al. [27] report results “enthusiastic” in the outcome of mould infections, particularly 
for aspergillosis. Our AMR for moulds is higher than that found for yeasts (45.4% vs. 6.2%;  
p = 0.026), probably due to late diagnosis because of non-specific clinical signs or to a poor 
sensitivity of conventional cultural methods. Alternative approaches, like the search for 
circulating antigens (BDG, GM), could represent a new way to achieve an early and valid 
diagnosis, but these methods are not accessible to all laboratories (e.g., due to high cost). For this 
reason, BDG and GM were performed only in patients with suspected moulds disease, resulting 
in the diagnosis of six cases of probable aspergillosis always with negative cultures [19].  
It is possible that our data concerning the low incidence of IFI from moulds may also be related to 
empirical antifungal therapy administered in 67% of enrolled patients, or to preventive measures   
(e.g., ventilation system cleaning and HEPA-LAF filtered room) usually adopted in four out of the  
nine enrolled hospitals. In fact, in these wards, a microbiological surveillance is regularly carried out 
on air, water and surfaces three times per year. In our 18 months experience, this surveillance yielded a 
poor environmental contamination: the only filamentous fungus detected was Alternaria alternata on a 
table surface, never identified as etiological agent of fungal disease. These results are in accordance with 
those of a previous environmental surveillance carried out in the operating theatre of one of the hospitals 
enrolled in the Aurora Project [28]. Also other authors [29,30] reported that air contamination was never 
detected in/outside the flow of HEPA-LAF rooms. So, the environmental protective facilities (air 
filtration and/or laminar airflow) could be of benefit for these high-risk patients, especially during 
treatment periods [31].  
There are other potential reasons explaining the low incidence of moulds IFI: a different geographic 
distribution of some fungal species [2,32], the absence of restructuration works in most enrolled Int. J. Mol. Sci. 2012, 13 784 
 
 
hospitals during the surveillance period, the meteorological conditions (e.g., low humidity and rainfall in 
winter, very hot summer), all factors promoting or limiting the environmental spread of fungal spores.  
Regarding bone marrow transplant patients, only three yeasts IFIs were reported in adults. Our data 
are in agreement with Pagano et al. [3] who showed that yeasts IFIs were more frequent than moulds 
diseases in recipients of HSCT.  
Regarding pediatric patients, the yeasts IFIs incidence was 2.6% (2 ALL and 1 NHL patients); these 
data support findings from Castagnola et al. [33] that found an incidence of 1.8%. About mould 
infections, no cases were detected in our pediatric patients. Zaoutis et al. [34], during a study of invasive 
aspergillosis (IA), reported the highest incidence in allogeneic bone marrow transplanted children (4.5%) 
and with acute myeloid leukemia (4%), but our enrolled children were mostly affected by ALL (77.2%) 
and had no transplantations. We reported no deaths for IFI in these patients, according to Kaya et al. [35] 
who described just one death among 21 pediatric leukemia patients with IFIs. 
5. Conclusions 
Our conflicting results with regard to the numbers and type of fungal infections might be mainly 
explained by the high rate (67%) of empirical antifungal therapy which usually results in a lower  
rate of proven/probable IFI, because of a less intense diagnostic work-up. Actually, BDG and GM 
determinations were performed only in patients with suspected infections as well as TC thorax scan 
was not regularly carried out and consequently BAL was exceptional. Although the diagnostic 
driven/pre-emptive approach was to prefer in Aurora Project experience because of the patients’ 
various fungal risk, the empirical approach was the prevalent one and the IFI rate inevitably penalized. 
Any effort should be made in order to facilitate the implementation of diagnostic microbiological test 
(i.e., BDG and GM) as well as radiological examinations in hematological patients’ IFI work-up. 
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